Neonatal SEPSIS
Conditions
Brief summary
Prospective, multinational, multicentre, observational cohort study of neonatal sepsis in partner institutions. The cohort study will be designed to evaluate health care utilization and current clinical practice and to assess risk factors for and outcomes of babies with neonatal sepsis (culture-negative and culture-positive).
Detailed description
1. NeoSEPSIS: Consecutive hospitalized babies with neonatal sepsis will be recruited and followed up until discharge from hospital or death (for a maximum of 28 days). A minimal neonatal sepsis dataset will determine (i) clinical presentations, associated features and risk factors (for example prematurity, SGA (small for gestational age)), (ii) rates of culture-positivity among babies with sepsis, (iii) current empirical treatment approaches (antimicrobials selected, dose, etc) (iv) outcomes of sepsis, including death, need for intensive care interventions and recurrence of sepsis during the follow-up period. Microbiological samples will be taken from sterile sites, blood and CSF, as clinically indicated and will be processed locally. 2. NeoBSI: Consecutive babies with positive blood/CSF cultures and sepsis will be recruited. Patient inclusion will be based on identification of relevant specified bacteria from blood / CSF cultures. In addition to the data collected for NeoSEPSIS, information will be collected on the isolates and their antimicrobial susceptibility patterns.
Interventions
OTHERMain study clinical sepsis
No intervention-Observational study
OTHERMicrobiology sub study
Analysis of Bacterial isolates
Sponsors
St George's, University of London
PENTA Foundation
Universiteit Antwerpen
Drugs for Neglected Diseases
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 60 Days
Healthy volunteers
No
Inclusion criteria
* In-patient in the hospital (NNU (Neonatal unit) or paediatric ward) of one of the partner institutions * Age \<60 days of age * Clinical suspicion of a new episode of sepsis (as defined below)\*\* together with planned treatment with IV antibiotics OR new episode of confirmed bacterial meningitis\^ OR new episode of infection in which a Carbapenem-resistant organism (CRO) is isolated from blood culture OR new episode of infection in which a candida species is isolated from blood culture * Informed consent from parent / guardian * Willingness to provide location information and to be contacted at 28 days from start of antibiotic treatment
Exclusion criteria
* • Previously enrolled in this study, unless readmitted and re-started on antibiotics before the 28 day follow-up limit is reached * Enrollment in any interventional trial * A serious, non-infective co-morbidity (other than prematurity), anticipated to cause death within 72 hours
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality Rate | 28 days | To estimate mortality rates in hospitalised infants less than 60 days of age who are being treated for significant sepsis (where significant is defined as presenting with 2 or more of the signs /symptoms listed in the inclusion criteria). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine the microbiological epidemiology, including antimicrobial susceptibility and resistance mechanisms, in infants with positive blood and/or cerebrospinal fluid culture | 28 days | The incidence of culture positive and culture negative sepsis (both bloodstream and CSF isolates) |
Countries
Bangladesh, Brazil, China, Greece, India, Italy, Kenya, South Africa, Thailand, Uganda, Vietnam
Outcome results
None listed